Hacettepe University   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Ankara Turkey (1967)

Organization Overview

First Clinical Trial
2003
NCT00590213
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Berna KURT | Board of Hacettepe University , Ankara, turkey | Ceren Devrim Şahin | Cigdem Yucel | Cigdem Yucel Ozcırpan | Duygu Karasan | First Affiliated Hospital of Guangxi Medical University | hacettepe üniversitesi | Hacettepe University | Hacettepe University, Ankara, Turkey | Hacettepe University Department of Neurology | Hacettepe University Faculty of Dentistry | Hacettepe University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation | Hacettepe University, Faculty of Medicine | Hacettepe University Faculty of Medicine Department of Psychiatry | Hacettepe University Faculty of Nursing | Hacettepe University Faculty of Pharmacy Department of Clinical Pharmacy/Ankara/Turkey | Hacettepe University, Faculty of Physical Therapy and Rehabilitation | Hacettepe University, Faculty of Physiotherapy and Rehabilitation | Hacettepe University Instute of Oncology Dept. of Basic Oncology | Hacettepe University Kastamonu Medical Faculty, Obstetrics and Gynecology, Ankara, Turkey, | Hacettepe University Medical Faculty | Hacettepe University Medical Faculty, Medical Oncology Department, Sihhiye 06100 Ankara, Turkey | Hacettepe University Scientific Research Projects Coordination Unit | Hacettepe Univ. Med. Fac | Head of the study | Kıvanç Akça | Münevver Şengül | Murat EMİRZEOĞLU | Ozgur Ozyuncu | volgamel@yahoo.com

Active Ingredients

Drugs in Phase 4 Trials (25)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (4 trials)

basiliximab (Simulect) (3 trials)

bicalutamide (casodex) (1 trial)

busulfan (Myleran) (3 trials)

clavulanate (Augmentin) (1 trial)

cyclophosphamide (cytoxan) (3 trials)

cyclosporine (sandimmune) (3 trials)

dexamethasone (1 trial)

dexmedetomidine (precedex) (2 trials)

fludarabine (fludara) (3 trials)

hyaluronidase (human recombinant) (Hylenex) (1 trial)

icotinib (Conmana) (1 trial)

lactobacillus reuteri (1 trial)

methotrexate (3 trials)

montelukast (singulair) (1 trial)

mycophenolate (CellCept) (4 trials)

nalmefene (revex) (1 trial)

naltrexone (revia) (2 trials)

procaine benzylpenicillin (novocaine) (1 trial)

propofol (diprivan) (1 trial)

ranibizumab (lucentis) (1 trial)

ruxolitinib (jakafi) (1 trial)

somatropin (protropin) (1 trial)

tacrolimus (prograf) (2 trials)

triptorelin (Trelstar) (1 trial)

Drugs in Phase 3 Trials (19)

allopurinol (zyloprim) (1 trial)

azacitidine (vidaza) (1 trial)

azithromycin (zithromax) (1 trial)

chidamide (1 trial)

cisplatin (platinol) (4 trials)

decitabine (dacogen) (1 trial)

docetaxel (taxotere) (4 trials)

endostatin (endostar) (5 trials)

favipiravir (1 trial)

febuxostat (uloric) (1 trial)

Filgrastim (neupogen) (1 trial)

goserelin (zoladex) (1 trial)

Homoharringtonine (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

nedaplatin (2 trials)

prednisone (meticorten) (1 trial)

secukinumab (cosentyx) (1 trial)

thalidomide (Thalomid) (1 trial)

venetoclax (venclexta) (1 trial)

Drugs in Phase 2 Trials (13)

anlotinib (2 trials)

autologous hematopoietic stem cells (2 trials)

capecitabine (xeloda) (2 trials)

cetuximab (erbitux) (1 trial)

cn128 (2 trials)

gemcitabine (gemzar) (1 trial)

gypenosides (1 trial)

lapatinib (tykerb) (2 trials)

paclitaxel (taxol) (1 trial)

sitravatinib (1 trial)

temozolomide (temodar) (1 trial)

tislelizumab (3 trials)

toripalimab (1 trial)

Drugs in Other Trials (27)

arginine (1 trial)

chlorhexidine (hibitane) (1 trial)

coconut oil (1 trial)

cow milk (1 trial)

denosumab (prolia) (1 trial)

donor regulatory t lymphocytes (1 trial)

edaravone (radicava) (1 trial)

esketamine (spravato) (1 trial)

ferrous sulfate (1 trial)

ferro zinc (1 trial)

folic acid (1 trial)

gliclazide (1 trial)

hemopoietic stem cell (1 trial)

hyaluronic acid (1 trial)

insulin detemir (Levemir) (1 trial)

inulin (1 trial)

kefir (1 trial)

lactobacillus casei (1 trial)

lidocaine (xylocaine) (1 trial)

morus nigra (1 trial)

n-butyl cyanoacrylate (1 trial)

olive (1 trial)

oxytocin (syntocinon) (1 trial)

remifentanil (ultiva) (1 trial)

sorafenib (nexavar) (1 trial)

thrombin (bovine) (Thrombostat) (1 trial)

voriconazole (vfend) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 4)

Asthma (Phase 4)

beta-Thalassemia (Phase 4)

Bile Duct Neoplasms (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 4)

Cardiomyopathies (Phase 2)

Choroidal Neovascularization (Phase 4)

Delirium (Phase 4)

Diarrhea (Phase 4)

Dwarfism, Pituitary (Phase 4)

Endocrine System Diseases (Phase 4)

Esophageal Neoplasms (Phase 2)

Food Hypersensitivity (Phase 4)

Glioblastoma (Phase 2)

Gout (Phase 3)

Graft vs Host Disease (Phase 4)

Hip Fractures (Phase 4)

HIV Infections (Phase 3)

Hypersensitivity (Phase 4)

Infarction (Phase 2)

Infertility (Phase 4)

Infertility, Female (Phase 4)

Iron Overload (Phase 2)

Leukemia (Phase 3)

Leukemia, Large Granular Lymphocytic (Phase 3)

Lung Neoplasms (Phase 4)

Macular Degeneration (Phase 4)

Myocardial Infarction (Phase 2)

Nasopharyngeal Carcinoma (Phase 3)

Neoplasm Metastasis (Phase 4)

Neovascularization, Pathologic (Phase 4)

Neuritis (Phase 2)

Optic Neuritis (Phase 2)

Pancreatic Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 4)

Psoriasis (Phase 3)

Thalassemia (Phase 4)

Uterine Cervical Neoplasms (Phase 3)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 63
  • # of Trial APIs: 84